Physician profile
Grigoriy I Labun
NPI 1144252685
$1,880.22
in general payments reported to CMS, 2019-2025
12 companies · $38.54 in 2025
The $38.54 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,642 · 2020: $158 · 2021: $20.13 · 2024: $21.82 · 2025: $38.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $38.54 · Food and Beverage: $21.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $38.54 |
| Food and Beverage | $21.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $506.85 | 2019-2024 | Abilify Asimtufii, Rexulti |
| Allergan, INC. | $270.08 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $231.16 | 2019-2020 | |
| Alkermes, INC. | $196.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $165.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.32 | 2019-2020 | |
| Lundbeck LLC | $129.95 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $94.35 | 2019 | |
| Indivior INC. | $51.40 | 2019-2020 | |
| Abbvie INC. | $40.82 | 2019-2021 | |
| Orexo US, INC. | $38.04 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigoriy Labun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.